Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

PURPOSE: Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities. PATIENTS AND METHODS: We conducted a multicenter phase II trial of imatinib in metastatic mucosal, acral, or chronically sun-damaged (CSD) melanoma with KIT amplifications and/o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Hodi, F. Stephen, Corless, Christopher L., Giobbie-Hurder, Anita, Fletcher, Jonathan A., Zhu, Meijun, Marino-Enriquez, Adrian, Friedlander, Philip, Gonzalez, Rene, Weber, Jeffrey S., Gajewski, Thomas F., O'Day, Steven J., Kim, Kevin B., Lawrence, Donald, Flaherty, Keith T., Luke, Jason J., Collichio, Frances A., Ernstoff, Marc S., Heinrich, Michael C., Beadling, Carol, Zukotynski, Katherine A., Yap, Jeffrey T., Van den Abbeele, Annick D., Demetri, George D., Fisher, David E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878082/
https://ncbi.nlm.nih.gov/pubmed/23775962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.7836
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados